Page 54 - Solid Tumors News Today

(0) - Updated Analysis Shows Median Overall Survival for TUKYSA Arm Extended to Two Years, with Benefit Maintained Across All Prespecified Patient Subgroups in HER2CLIMB Trial - - Results Further Support TUKYSA as Well-Tolerated Treatment Option That Improves Survival in Patients with Previously Treated Metastatic HER2-Positive Breast Cancer With and Without Brain Metastases - Seagen Inc. (Nasdaq:SGEN) today announced that improvements in overall survival (OS) and progression-free survival ...

Seagen Announces Long-Term Results from TUKYSA® (tucatinib) Pivotal Trial in Patients with HER2-Positive Breast Cancer During the Virtual Scientific Program of the 2021 ASCO Annual Meeting - read this article along with other careers information, tips and advice on BioSpace

The wide-ranging market information of the CAR-T Therapy Treatment Market report will surely grow business and improve return on investment (ROI). This market research report gives CAGR values along with their fluctuations for the specific forecast period. The market report has been prepared by taking into account s...

Global Drugs for Solid Tumors Market 2021 Growth Analysis, Opportunities, Figures with Sweeping Sales 7Newswire 03 May 2021, 21:33 GMT+10 The Global Drugs for Solid Tumors Market Report offers an eclectic perceptive of the market, illuminating major facets that impact, affect, boost or hinder the market growth. It highlights how the global market has been performed and how it will be performing in the near future. The report also provides important insights into scope, establishment, profitabil...

Share this article Share this article HORSHAM, Pa., May 21, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has granted the accelerated approval of RYBREVANT TM (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose di...

Amgen To Showcase New Data From Oncology Portfolio At ASCO 2021 LUMAKRAS™ (Sotorasib)¹ Overall Survival and Biomarker Subgroup Analyses From Registrational Phase 2 CodeBreaK 100 Trial in KRAS G12C-Mutated Non-Small Cell Lung Cancer New Data From the Phase 2 FIGHT Trial with Bemarituzumab in Advanced Gastric and Gastroesophageal Junction Cancers News provided by Share this article Share this article THOUSAND OAKS, Calif., May 19, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that ...

Press release content from PR Newswire. The AP news staff was not involved in its creation.

We are excited to welcome Prof. Dennis Discher from University of Pennsylvania to Tissue Talks on Wednesday, May 12th at 3:00PM EST as he presents, "Convergent Science Approaches to Solid Tumors: From Mechano-genetic Variation to Macrophage-initiated Vaccination."   ABOUT TISSUE TALKS Join us every Wednesday at 3:00PM EDT for the wildly popular Tissue Talks, our weekly webinar series hosted by Dr. Gordana Vunjak-Novakovic and the Laboratory for Stem Cells and Tissue Engineering. Don�...

Applications Based on Progression-Free Survival, Overall Survival, and Objective Response Rate Data From Respective Pivotal Phase 3 Trials Merck known as MSD outside the United States and Canada, and Eisai Inc. today announced that the U.S. Food and Drug Administration has accepted and granted priority review for applications seeking two new approvals for the combination of KEYTRUDA, Merck’s anti-PD-1 therapy, … Applications Based on Progression-Free Survival, Overall Survival, and Objecti...

Global Drugs for Solid Tumors Market 2021 Growth Analysis, Opportunities, Figures with Sweeping Sales 7Newswire 03 May 2021, 21:33 GMT+10 The Global Drugs for Solid Tumors Market Report offers an eclectic perceptive of the market, illuminating major facets that impact, affect, boost or hinder the market growth. It highlights how the global market has been performed and how it will be performing in the near future. The report also provides important insights into scope, establishment, profitabil...